At its meeting on 15 May 2023, the Transparency Council adopted Opinion No. 97/2023 on the inclusion in the reimbursement procedure of medicines containing the active substance carboplatin for selected off-label indications.
At its meeting on 15 May 2023, the Transparency Council adopted Opinion No. 97/2023 on the inclusion in the reimbursement procedure of medicines containing the active substance carboplatin for selected off-label indications.